A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
Trial Details
- NCT ID
- NCT07589257
- Phase
- PHASE2
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- Locations (sample)
- Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
- Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study pr…
- Male or female adults aged 18 to 75 years at the time of signing the ICF.
- Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI:…
- Karnofsky Performance Status (KPS) score ≥ 60.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →